Global CRO Footprint 360biolabs operates as part of BioAgilytix with facilities in Melbourne and Brisbane and a global team in the United States and Europe, enabling end-to-end support for multi-region clinical trials. This positions the company well for sponsors seeking a single partner to manage cross-border bioanalytical work across Phase I-III.

Phase Capabilities Across The lab offers Phase I-III bioanalytical services including PK/PD, LC/MS, Flow Cytometry, Biomarkers, Molecular Assays and Central Laboratory support such as kit production and lab manuals. This breadth allows a one-stop shop for sponsors looking to consolidate vendors and streamline method development, validation and transfer.

Regulatory Grade Compliance Operations adhere to GLP, GCP and ISO17025 with alignment to ICH, FDA and EMA standards, supporting quality and audit readiness. This compliance profile makes them attractive to sponsors with stringent regulatory requirements and bid opportunities that demand proven quality systems.

Integrated Bioanalysis Network In addition to analytical services, 360biolabs emphasizes method development, tech transfer and assay validation under tight quality systems, facilitating standardized workflows across sites. This enables scalable support for multicenter trials and easier onboarding for new programs within a CRO network.

Cross-border Lab Network The Australian hub complements a broader global footprint, with the BioAgilytix acquisition enhancing cross-border collaboration and speed-to-first-patient. For BD teams, this translates into quicker study start-up, harmonized analytics and a single point of contact for multi-country programs.